文献速递肝病

肝硬化危重患者有无肝移植的生存情况:20年经验

Survival With and Without Liver Transplantation in Critically Ill Patients With Cirrhosis: A 20-Year Experience.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-06-03

该回顾性队列研究纳入2000年1月至2020年3月连续成人肝硬化患者共1688例,首次紧急入住单中心肝病重症监护病房。无移植生存率与慢加急性肝衰竭(ACLF)分级密切相关(P<.001),2000-2009年为51.9%,2010-2020年升至70.6%(P<.001),ACLF 3级改善较小(31.0%升至45.8%,P<.001)。随访期间280例接受肝移植,移植比例从12.6%升至20.2%,移植后1年和5年生存率分别为91%和81.9%。

要点

  • 无移植生存率与ACLF分级密切相关(P<.001),ACLF 3级改善幅度小于整体。
  • 无移植生存率2000-2009年51.9%升至2010-2020年70.6%(P<.001),2010-2014年与2015-2020年无差异。
  • 随访期间280例接受肝移植,移植后1年和5年生存率分别为91%和81.9%。

核心结论

  • 无移植生存率现已趋于平台期,需要新干预措施改善ACLF患者的生存。
  • 肝移植使用率不高但结局优良。
  • ACLF幸存者应密切随访,并强烈考虑进行移植评估。

研究设计与样本

  • 回顾性队列研究,纳入2000年1月至2020年3月连续成人肝硬化患者,首次紧急入住单中心肝病重症监护病房(LITU),共1688例(62%男性;中位年龄52岁[四分位距43-60岁];终末期肝病模型评分28[四分位距18-37])。
  • ACLF分级分为0级(无ACLF)、1或2级、3级;采用时间-事件分析比较生存。

主要发现

  • 23%无ACLF,39%为ACLF 1或2级,37%为ACLF 3级;无移植生存率与ACLF分级密切相关(P<.001)。
  • LITU无移植生存率2000-2009年为51.9%,2010-2020年升至70.6%(P<.001);ACLF 3级改善较小,从31.0%升至45.8%(P<.001)。
  • 2010-2014年与2015-2020年无移植生存率无差异。
  • 长期无移植生存率差,LITU入住后1年无移植存活患者不足20%。
  • 随访期间280例接受肝移植,移植比例从2000-2009年的12.6%升至2010-2020年的20.2%,移植后1年和5年生存率分别为91%和81.9%。

临床怎么用

  • 作者认为,ACLF幸存者应密切随访,并强烈考虑进行移植评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In 2015, we reported the outcome of patients with cirrhotic chronic liver disease with unplanned admission to a specialist single-center Liver Intensive Therapy Unit (LITU) demonstrating progressive improvement in short-term survival. We investigated if this and long-term survival had continued to improve, and its relation to use and outcome of liver transplantation (LT). METHODS: A retrospective cohort study of consecutive adult patients with cirrhosis and unplanned emergent first LITU admission January 2000 to March 2020. Demographic and clinical variables were obtained at admission; acute-on-chronic liver failure (ACLF) grade was categorized as 0 (no ACLF), 1 or 2, or 3. Transplant-free survival (TFS) and LT practices were characterized and survival compared using time-to-event analysis. RESULTS: The cohort comprised 1688 patients (62% male; median age 52 years [interquartile range, 43-60 years]) with Model for End-Stage Liver Disease score 28 (interquartile range, 18-37); 23% had no ACLF, 39% had ACLF 1 or 2, and 37% had ACLF 3; TFS closely related to ACLF grade (P < .001). LITU TFS was 51.9% in 2000 to 2009, increasing to 70.6% in 2010 to 2020 (P < .001); improvement for ACLF 3 was smaller: 31.0% to 45.8%, (P < .001). There was no difference in TFS survival in 2010 to 2014 vs 2015 to 2020. Long-term TFS was poor with <20% of patients alive without LT 1 year after LITU admission. During follow-up, 280 underwent LT: the proportion transplanted increased from 12.6% in 2000 to 2009 to 20.2% in 2010 to 2020, with 1- and 5-year post-transplant survival of 91% and 81.9%. CONCLUSIONS: TFS has now plateaued with need for novel interventions to improve survival in ACLF. LT is infrequently utilized but has excellent outcomes. ACLF survivors should be closely followed up with strong consideration given for transplant assessment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bernal W, Bittermann T, Sheth R, et al. Survival With and Without Liver Transplantation in Critically Ill Patients With Cirrhosis: A 20-Year Experience. Clin Gastroenterol Hepatol. 2025. PMID: 40473089. doi:10.1016/j.cgh.2025.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。